Company Overview of Laboratorios Litaphar S.A.
Laboratorios Litaphar, S.A. develops generic medicines and pharmaceutical products through bioequivalence research and elaboration. The company’s products include Enalapril APHAR, Omeprazol APHAR, Claritromicina APHAR, Lovastatina APHAR, and Furosemida APHAR for treatment of hypertension, cardiac insufficiency, gastric and duodenal ulcers, respiratory tract infections, and skin infections. The company was founded in 2001 and is based in Azpeitia, Spain with an additional office in Madrid, Spain. As of May 19, 2006, Laboratorios Litaphar S.A. operates as a subsidiary of Reddy Pharma Iberia, S.A.
C/ Orendaundi, 9
Founded in 2001
34 902 99 97 71
34 902 99 98 81
Key Executives for Laboratorios Litaphar S.A.
Laboratorios Litaphar S.A. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Ability Pharmaceuticals, S.L.||Europe|
|Activery Biotech SL||Europe|
|Aelix Therapeutics SL||Europe|
|AlbaJuna Therapeutics SL||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Laboratorios Litaphar S.A., please visit www.litaphar.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.